Straumann Holding AG / CH1175448666

   

All figures refer to continuing operations in CHF million / margin changes rounded	H1 2025		H1 2024
	IFRS	CORE1		IFRS	CORE1
Revenue	1 348.2	1 348.2		1 273.3	1 273.3
Change CHF		5.9%			11.3%
Change (CER[2])		10.2%			17.6%
Change organic		10.2%			16.1%
Gross profit	968.9	972.0		918.4	922.8
Margin	71.9%	72.1%		72.1%	72.5%
Margin change CHF		(40bps)			(280bps)
Margin change (CER2)		10bps			(180bps)
EBITDA	418.2	428.5		406.5	415.9
Margin	31.0%	31.8%		31.9%	32.7%
Margin change CHF		(90bps)			(120bps)
Margin change (CER2)		0bps			50bps
EBIT	329.6	358.1		336.1	354.4
Margin	24.4%	26.6%		26.4%	27.8%
Margin change CHF		(130bps)			(120bps)
Margin change (CER2)		(40bps)			70bps
Net result	238.2	265.7		268.2	282.1
Margin	17.7%	19.7%		21.1%	22.2%
Margin change CHF		(250bps)			0bps
Basic EPS (in CHF)	1.49	1.66		1.67	1.76
Free cash flow	113.0			145.3
Margin	8.4%			11.4%
Headcount (end of June)	11 948			11 145

Basel, August 13, 2025: Straumann Group reported revenue of CHF 1.3 billion for the first half of 2025, achieving +10.2% organic revenue growth or +5.9% in Swiss francs. In the second quarter, revenue reached CHF 667.5 million, with +9.3% organic growth or +1.9% in Swiss francs year-on-year supported by all regions. Europe Middle East and Africa (EMEA), Asia-Pacific (APAC) and Latin America (LATAM) posted strong performances, underpinned by sustained demand and strong commercial execution. North America delivered a stable growth rate quarter over quarter, leading to continued market share gains within an ongoing challenging US market environment. Second-quarter growth was driven by strong contributions across all business segments. In premium implantology, high demand — led by iEXCEL and BLT — continued to fuel expansion. Neodent’s geographic growth drove solid performance in challenger brands. Digital solutions and orthodontics delivered double-digit growth, supported by growing demand for integrated workflows. Digital innovation accelerated with the launch of the Straumann AXS platform and Straumann Falcon, both gaining traction. The commercial launch of the MIDAS 3D printer in June marked a key milestone in Straumann’s chairside restorative workflow, while ongoing progress in intraoral scanning — driven by the SIRIOS scanner — reinforced the Group’s commitment to a comprehensive, cloud-based digital ecosystem.   Guillaume Daniellot, Chief Executive Officer, commented: “We delivered a strong second quarter and half-year results, while navigating ongoing macroeconomic headwinds and increased global geopolitical uncertainty. Our broad-based growth across regions and segments highlights the strength of our portfolio, the dedication of our teams, and the trust placed in us by customers around the world. I'm particularly encouraged by the momentum in digital dentistry — from the successful rollout of iEXCEL, Straumann AXS to the positive early response to our MIDAS 3D printer. These developments reaffirm our strategy to build a fully digital, integrated ecosystem that meets the evolving needs of dental professionals globally.”   In the second quarter, revenue in Swiss francs faced strong headwinds from unfavorable currency developments, particularly due to the US dollar, Chinese renminbi, and Brazilian real. Despite these external pressures, the Group maintained its strategic focus and continued to invest significantly in capacity expansion, education, and digital transformation. The core EBIT margin remained robust at 27.3% on a constant 2024 currency rate basis, or 26.6% at current exchange rates.     STRATEGIC PROGRESS IN THE second quarter   2025 new product launches are gaining traction – iEXCEL launch in Europe successful The iEXCEL high-performance implant system received excellent feedback from clinicians following its successful global launch, including APAC and EMEA. Designed for clinical versatility and workflow simplicity, iEXCEL strengthens Straumann’s premium implantology offering. It supports immediate protocols and streamlines surgical procedures. A key milestone in July was the launch of the SLA version of the iEXCEL C-Line. This addition is strategically positioned to broaden access while upholding high standards of clinical performance and quality. Straumann Pro Arch is increasingly embracing digital workflows for full-arch solutions, with the integration of Straumann EXACT — a high-precision system that includes a scan body to enhance accuracy and ensure a seamless transition from temporary to final implant restorations. It supports clinicians at every stage of the treatment journey — from the initial digital scan to the final prosthetic delivery. By streamlining what was once a highly complex process, it not only saves valuable time for clinicians but, most importantly, enhances the overall experience and comfort for patients undergoing full-arch tooth replacement. In parallel, the Straumann chairside workflow solution with the MIDAS 3D printer, developed in collaboration with SprintRay, has been fully implemented into the Straumann AXS digital platform since its launch in June. This marks the completion of Straumann’s fully integrated chairside workflow — connecting intraoral scanning, planning, and in-practice 3D printing within an open, cloud-based ecosystem. These advancements reinforce Straumann’s leadership in digitally powered oral care and meet the growing demand for efficient, end-to-end solutions.   Group leverages global manufacturing footprint and continues to invest in local production, supporting growth, resilience, and innovation in key markets The Group is advancing its global growth strategy with the phased launch of its new Shanghai campus, which received its licenses to start producing Straumann implants. Designed as both a high-tech manufacturing site and a clinical education hub, the campus supports long-term growth and customer engagement in China. In anticipation of the country’s volume-based procurement (VBP) 2.0 cycle in 2026, the Group has begun transferring production for the Chinese market from Villeret, Switzerland, to Shanghai.   While localizing production for China, Straumann invests in the Villeret site Straumann Group remains firmly committed to its Villeret site in Switzerland. The company has announced an investment of CHF 60–80 million over the next five years to enhance it as a center of excellence for innovation and precision manufacturing, with a focus on high value-added products like the iEXCEL implant system.   Global manufacturing network comprises 19 sites worldwide The Group’s global manufacturing network provides agility, flexibility, and resilience. Its diversified supply chain supports responsiveness to regional market needs, while a strong local manufacturing presence — particularly in the United States — ensures supply continuity. In the U.S., the majority of Straumann’s premium implants, prosthetics, regenerative solutions, and aligners are produced domestically.   Straumann Group acquires maxon dental joint venture to expand ceramic implant capabilities
Straumann Group has increased its stake in maxon dental GmbH from 49% to 100%, gaining full ownership of one of the most advanced technology centers in ceramic implantology. Located in Kenzingen, Germany, maxon dental developed the world’s first two-piece ceramic implant system using proprietary ceramic injection molding (CIM) technology. This acquisition secures a unique innovation platform for Straumann Group, strengthening its position in ceramic solutions and enabling future growth in this field. All 13 employees and the site will be retained, with plans to expand ceramic injection activities.     REGIONAL PERFORMANCEs in the Second quarter   Strong growth in EMEA driven by implantology and digital innovation The Europe, Middle East, and Africa (EMEA) region reported revenue of CHF 270.4 million in the second quarter, delivering solid organic growth of 8.2%. Strong performances in Germany, Spain, Turkey and several Eastern European countries supported the overall regional growth. Implantology remained the main growth engine, with both premium and challenger brands outperforming. Neodent and Anthogyr gained momentum through major events in Barcelona and Cannes, engaging hundreds of dental professionals and generating strong leads. Straumann’s premium offering continued to grow, supported by the full launch of iEXCEL at IDS (International Dental Show) 2025 and EuroPerio in May, along with promotional tours driving digital adoption. Digital solutions were a key contributor, with the Straumann AXS platform — launched at the IDS — maintaining high engagement and the new SIRIOS intraoral scanner gaining strong traction. In addition, ClearCorrect continued to gain momentum in the general practitioner space.   Resilient growth in North America amid ongoing market challenges The North America region reported revenue of CHF 170.7 million in the second quarter, achieving solid organic growth of 2.7%. Market conditions remained difficult, shaped by ongoing macroeconomic and geopolitical uncertainty, which continued to drive cautious consumer spending — particularly impacting out-of-pocket dental treatments and patient flow. Despite these challenges, the Group delivered a resilient performance, supported by implantology and rising adoption of digital workflows. Implantology remained the core growth driver, with the combined strength of the premium portfolio and Neodent, the Group’s leading challenger brand. Digital solutions also contributed positively, driven by the strong performance of the SIRIOS intraoral scanner. The MIDAS 3D printer, launched in June, attracted significant interest from dental service organizations (DSOs), reflecting growing demand for chairside workflows and integrated solutions. Meanwhile, the orthodontics segment remained soft.   Asia pacific sustains strong growth driven by implantology and digital launches Asia Pacific delivered a strong second quarter, with revenue of CHF 169.3 million and organic growth of 16.4%. Growth in China remained strong, supported by strong patient flow resulting from the long-term structural impact of the volume-based procurement (VBP) initiative, which raised awareness and improved the affordability of implants. Solid contributions also came from Australia, Japan, India, and Thailand. Momentum was fueled by the continued strength of the implantology business, supported by both premium and challenger brands, notably Straumann and Neodent. Neodent advanced its global footprint with further expansion in Australia, India, Japan, and Vietnam. The launch of the latest innovations played an important role, with the successful rollout of the intraoral scanner SIRIOS, the launch of iEXCEL in Australia, and the Straumann AXS digital platform in Australia, Thailand, Singapore, and Japan. Continued investments in education and customer engagement further reinforced the Group’s position in the region, which remains well positioned for sustained growth.   Latin America shows strong growth through strong brand portfolio and digital adoption In the second quarter, Latin America achieved organic growth of 16.2%, generating CHF 57.1 million in revenue. Growth was primarily fueled by the challenger segment, with Neodent delivering strong results across the region — particularly in Brazil, its home market, where brand recognition and customer loyalty remain high. The premium implantology business also performed well in Brazil. Brazil and Mexico were the top contributors, both recording mid-teens growth, while Argentina began to gain momentum. Colombia continued to face headwinds due to political uncertainty, whereas other countries remained stable. Digital solutions played a key role in supporting regional performance, especially in Brazil, where the SIRIOS intraoral scanner delivered strong results. On the premium side, Straumann ramped up activities, including the Straumann LATAM Congress held in May and new ITI training sessions launched in June. Additionally, ClearCorrect performed well, contributing positively to the region’s overall performance.    

REVENUE BY REGION	Q2 2025	Q2 2024	H1 2025	H1 2024
Figures refer to continuing operations, in CHF million
Europe, Middle East & Africa (EMEA)	270.4	261.3	550.3	519.8
Change CHF	3.5%	11.6%	5.9%	6.9%
Change (CER[3])	8.2%	15.5%	9.1%	13.8%
Change organic	8.2%	12.4%	9.1%	10.8%
% of Group total	40.5%	39.9%	40.8%	40.8%
North America (NAM)	170.7	181.4	355.9	359.1
Change CHF	(5.9%)	4.7%	(0.9%)	1.1%
Change (CER3)	2.7%	5.3%	2.2%	4.5%
Change organic	2.7%	5.3%	2.2%	4.5%
% of Group total	25.6%	27.7%	26.4%	28.2%
Asia Pacific (APAC)	169.3	154.6	331.5	285.4
Change CHF	9.5%	26.4%	16.2%	41.2%
Change (CER3)	16.4%	34.7%	19.6%	53.6%
Change organic	16.4%	33.8%	19.6%	52.3%
% of Group total	25.4%	23.6%	24.6%	22.4%
Latin America (LATAM)	57.1	57.7	110.5	109.0
Change CHF	(1.0%)	8.4%	1.3%	8.6%
Change (CER3)	16.2%	14.9%	17.5%	13.3%
Change organic	16.2%	14.9%	17.5%	13.2%
% of Group total	8.6%	8.8%	8.2%	8.6%
Group	667.5	654.9	1348.2	1273.3
Change CHF	1.9%	12.4%	5.9%	11.3%
Change (CER3)	9.3%	16.2%	10.2%	17.6%
Change organic	9.3%	14.8%	10.2%	16.1%

    OPERATIONS AND FINANCES[4] In addition to the results reported under IFRS accounting standards, the Group presents “core” results to facilitate a like-for-like comparison. In the first six months of 2025, the following pre-tax effects were defined as non-core items: Amortization of acquisition-related intangible assets and changes in the fair value of related contingent considerations, amounting to CHF 13 million Impairment costs of CHF 10 million Restructuring costs of CHF 7 million Litigation costs of CHF 3 million   A reconciliation table and detailed information are provided on page 10ff. of this media release.     Gross profit margin remains at a high level In the first six months of this fiscal year, the Group’s strong topline growth led to a core gross profit of CHF 972.0 million, which is a currency-adjusted increase of CHF 91.2 million. The corresponding gross margin was slightly higher than last year at 72.1%, despite a 50 basis point decrease caused by negative currency effects compared to 2024. The one-off impacts from the Shanghai Campus and tariffs were effectively offset by a favorable portfolio mix, which contributed positively to the margin performance.   Core EBIT margin of 26.6% In the first six months, currency-adjusted EBIT increased year over year reaching CHF 358 million. The core EBIT margin was 26.6%, including strong currency headwinds, and stood 130 basis points lower than in the same period last year. Currency effects accounted for a 90 basis point reduction, mainly due to the weakening of the Euro, US dollar, Chinese renminbi, and several emerging market currencies.   In the period under review, core distribution expenses rose by CHF 4 million to CHF 242 million, due to higher sales-force expenses and logistics costs. Core administrative expenses increased by CHF 40 million to CHF 377 million primarily due to rising investments in Research and Development and Data & Technology.   Core net profit reached CHF 266 million Core net financial expenses increased by CHF 17 million to CHF 24 million. This primarily reflects a more volatile currency environment compared to last year. Income taxes amounted to CHF 60 million, resulting in an income tax rate of 18.3%. Core net profit reached CHF 266 million, resulting in a margin of 19.7%. Core basic earnings per share decreased from CHF 1.76 to CHF 1.66, compared to the prior-year period.   Free cash flow lower year-on-year, yet still solid Free cash flow generation was CHF 113 million, CHF 32 million lower than in the prior year which was mainly related to CHF 29 million higher capital expenditure. Capital expenditure remained at a high level, totaling CHF 113 million, reflecting the Group’s continued commitment to expanding production capacity and advancing digital transformation. Key investments included the expansion of the manufacturing site in Curitiba, Brazil, Medentika in Calw, Germany, and the development of the new Shanghai campus which will serve as a hub for manufacturing, education, and innovation in China.   The cash position on 30 June 2025 was at CHF 247 million.     OUTLOOK 2025 Confirmed - BARRING UNFORESEEN CIRCUMSTANCES The Group confirms the full-year guidance and remains confident in its ability to continue gaining market share within the estimated global addressable market of approximately CHF 20 billion. While macroeconomic uncertainties — including rising trade tariffs and regional demand fluctuations — are expected to persist, the Group’s strong fundamentals provide resilience. Its confidence is underpinned by its innovation capabilities, a broad global footprint also in terms of manufacturing sites, a differentiated global value proposition covering all price points, and consistent execution driven by the strong culture. In addition, the Group emphasizes its ongoing investments in regional production capacity, digital transformation and extensive training initiatives, enabling more clinicians to perform implant and orthodontic procedures. As a result, the Group confirms its outlook for 2025, aiming to achieve organic revenue growth in the high single-digit percentage range, with a 30 to 60 basis points improvement of the core EBIT margin at constant 2024 currency rates. ***   Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland      Phone: +41 (0)61 965 11 11 Homepage: www.straumann-group.com   Contacts:  

Corporate Communication Silvia Dobry:  +41 (0)61 965 15 62 Doris Horn:    +41 (0)61 965 19 74 E-mail: corporate.communication@straumann.com

Investor Relations Marcel Kellerhals:   +41 (0)61 965 17 51                       Derya Güzel:           +41 (0)61 965 18 76 E-mail: investor.relations@straumann.com

    ANALYSTS’ AND MEDIA CONFERENCE CALL Straumann will present its 2025 half-year results to representatives of the financial community and media in a webcast conference call today at 10.30 a.m. CEST. The webcast can be accessed via www.straumann-group.com/webcast. A replay of the webcast will be available after the conference.   If you intend to ask a question during the Q&A session, we kindly ask you to pre-register for the conference call through this link. We also recommend that you download the presentation file in advance using the direct link in this media release before joining the conference call.     Presentation The conference presentation slides are attached to this release and available on the Media and Investors pages at www.straumann-group.com.   UPCOMING CORPORATE / INVESTOR EVENTS  

2025	Event	Location
August 14 – 15	Swiss Roadshow	Zurich, Geneva
September 3	Wells Fargo Healthcare Conference	Boston
September 4	Goldman Sachs Medtech Conference	London
September 8	Morgan Stanley Healthcare Conference	New York
September 9 – 10	Canada Roadshow	Toronto – Montreal
September 23	UBS Conference	Wolfsberg
September 25	Bank of America Healthcare Conference	London
Sep 30 – Oct 28	Quiet period
October 29	Third quarter 2025 results	Webcast

  Disclaimer This press release contains forward-looking statements that reflect the current views, beliefs and expectations of management at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events, or otherwise. This release constitutes neither an offer to sell nor a solicitation to buy any securities.          

[1] The “core” figures in this document exclude M&A effects from purchase-price allocation (PPA) amortization and related changes of contingent considerations, impairments, restructuring expenses, legal cases, consolidation result of former associates, and other non-recurring incidents. Details and a reconciliation of the reported and core income statement are provided on pages 10ff.

[2] Constant exchange rate (CER) equals prior-year figures at 2025 currency exchange rates

[3] Constant exchange rate (CER) equals prior-year figures at 2025 currency exchange rates

[4] The numbers stated in the below paragraph reflect continuing operations